Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism

E. Martignoni; M. Cosentino; M. Ferrari; G. Porta; E. Mattarucchi; F. Marino; S. Lecchini; G. Nappi

doi:10.1212/01.wnl.0000187066.81162.70

Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism

E. Martignoni, M. Cosentino, M. Ferrari, G. Porta, E. Mattarucchi, F. Marino, S. Lecchini, G. Nappi

Fondazione "Istituto Neurologico Casimiro Mondino"

Research output: Contribution to journal › Article › peer-review

Abstract

The authors report two cases of catechol-O-methyltransferase (COMT) inhibitor-induced asymptomatic hepatic dysfunction in women with Parkinson disease. The patients were genotyped for the UDP-glucuronosyltransferase (UGT) 1A9 gene (which encodes the main COMT inhibitor-metabolizing enzyme), and found to carry mutations leading to defective glucuronidation activity. This suggests that UGT1A9 poor metabolizer genotype(s) may be a predisposing factor for COMT inhibitor-induced hepatotoxicity.

Original language	English
Pages (from-to)	1820-1822
Number of pages	3
Journal	Neurology
Volume	65
Issue number	11
DOIs	https://doi.org/10.1212/01.wnl.0000187066.81162.70
Publication status	Published - Dec 2005

ASJC Scopus subject areas

Neuroscience(all)

Access to Document

10.1212/01.wnl.0000187066.81162.70

Fingerprint Dive into the research topics of 'Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism'. Together they form a unique fingerprint.

Cite this

@article{a3f361f3e6c241098801185c721a417d,

title = "Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism",

abstract = "The authors report two cases of catechol-O-methyltransferase (COMT) inhibitor-induced asymptomatic hepatic dysfunction in women with Parkinson disease. The patients were genotyped for the UDP-glucuronosyltransferase (UGT) 1A9 gene (which encodes the main COMT inhibitor-metabolizing enzyme), and found to carry mutations leading to defective glucuronidation activity. This suggests that UGT1A9 poor metabolizer genotype(s) may be a predisposing factor for COMT inhibitor-induced hepatotoxicity.",

author = "E. Martignoni and M. Cosentino and M. Ferrari and G. Porta and E. Mattarucchi and F. Marino and S. Lecchini and G. Nappi",

year = "2005",

month = dec,

doi = "10.1212/01.wnl.0000187066.81162.70",

language = "English",

volume = "65",

pages = "1820--1822",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "11",

}

TY - JOUR

T1 - Two patients with COMT inhibitor-induced hepatic dysfunction and UGT1A9 genetic polymorphism

AU - Martignoni, E.

AU - Cosentino, M.

AU - Ferrari, M.

AU - Porta, G.

AU - Mattarucchi, E.

AU - Marino, F.

AU - Lecchini, S.

AU - Nappi, G.

PY - 2005/12

Y1 - 2005/12

N2 - The authors report two cases of catechol-O-methyltransferase (COMT) inhibitor-induced asymptomatic hepatic dysfunction in women with Parkinson disease. The patients were genotyped for the UDP-glucuronosyltransferase (UGT) 1A9 gene (which encodes the main COMT inhibitor-metabolizing enzyme), and found to carry mutations leading to defective glucuronidation activity. This suggests that UGT1A9 poor metabolizer genotype(s) may be a predisposing factor for COMT inhibitor-induced hepatotoxicity.

AB - The authors report two cases of catechol-O-methyltransferase (COMT) inhibitor-induced asymptomatic hepatic dysfunction in women with Parkinson disease. The patients were genotyped for the UDP-glucuronosyltransferase (UGT) 1A9 gene (which encodes the main COMT inhibitor-metabolizing enzyme), and found to carry mutations leading to defective glucuronidation activity. This suggests that UGT1A9 poor metabolizer genotype(s) may be a predisposing factor for COMT inhibitor-induced hepatotoxicity.

UR - http://www.scopus.com/inward/record.url?scp=33645094707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645094707&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000187066.81162.70

DO - 10.1212/01.wnl.0000187066.81162.70

M3 - Article

C2 - 16344532

AN - SCOPUS:33645094707

VL - 65

SP - 1820

EP - 1822

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 11

ER -